https://www.selleckchem.com/products/cc-122.html
The safety and tolerability profile of oral semaglutide across the PIONEER clinical trial program was consistent with the GLP-1RA class. The most common adverse events were gastrointestinal (GI) (eg, nausea, diarrhea, and vomiting), which were typically mild to moderate and transient. In clinical practice, oral semaglutide expands the treatment options available to patients with T2D and can be considered in patient populations suitable for injectable GLP-1RAs.The first tablet formulation of a glucagon-like peptide-1 receptor agonist(GLP-
Like
Comment
Share
